What Disc Medicine (IRON)'s Bitopertin Fast-Track Review and Rising R&D Spend Mean for Shareholders [Yahoo! Finance]
Disc Medicine, Inc. (IRON)
Company Research
Source: Yahoo! Finance
by the receipt of the FDA Commissioner's National Priority Voucher for expedited review, and reported increased research and development spending in its latest quarterly results. This regulatory advancement and pipeline progress come as the company continues to report significant net losses, underscoring investor focus on future commercialization potential and upcoming clinical trial data releases. We'll explore how the regulatory momentum from bitopertin's fast-track review shapes Disc Medicine's investment narrative amid heightened R&D investment. This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality What Is Disc Medicine's Investment Narrative? Shareholders in Disc Medicine are being asked to believe in the company's ability to turn bold R&D spending and major clinical milestones into future commercial success, with bitopertin's recent FDA priority review nod acting as a crucial catalyst. The accelerated approval
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRONGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRONPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRONGlobeNewswire
- Disc Medicine (NASDAQ:IRON) had its "overweight" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Disc Medicine (NASDAQ:IRON) had its "market perform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
IRON
Earnings
- 11/6/25 - Miss
IRON
Sec Filings
- 1/21/26 - Form 4
- 1/12/26 - Form 8-K
- 1/7/26 - Form SCHEDULE
- IRON's page on the SEC website